search
The speaker emphasizes the pivotal role of randomized trials as the gold standard for comparing disease interventions, crucial for FDA approval. The phases of clinical trials, ranging from safety assessments (Phase 1) to large-scale efficacy studies (Phase 3), are outlined. The event underscores the importance of phase two and three trials in addressing diseases like lung and esophageal cancer, with a focus on improving survival rates.
Challenges in clinical trials, such as low patient enrollment and the need for greater openness to potential candidates, are highlighted. The speaker encourages a collective effort to push for increased patient recruitment. The urgency stems from the dismal five-year survival rates of lung and esophageal cancer, emphasizing the need for innovative techniques and strategies. The event serves as a call to action, urging attendees to be the driving force in directing trial development and recruitment, echoing Theodore Roosevelt's call to be "the man in the arena" and daring greatly to advance medical research.
